Researchers identified the clinical features that distinguished acute lymphoblastic leukemia from juvenile idiopathic arthritis in children with persistent bone or joint pain for at least 1 month.
Researchers assessed the association between oral health, microbial communities and juvenile idiopathic arthritis.
The FDA has approved RediTrex (methotrexate injection; Cumberland) for the management of patients with severe, active rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis, who are intolerant of or had an inadequate response to first-line therapy.
Study researchers aimed to identify undiagnosed cases of arthropathy of Down syndrome (A-DS), time to diagnosis, and clinical, laboratory and radiologic features of A-DS at diagnosis.
Researchers evaluated the role of adenosine deaminase 2 as a novel biomarker of macrophage activation syndrome.
Researchers evaluated the efficacy and safety of abatacept in pediatric patients with polyarticular-course juvenile idiopathic arthritis.
Investigators analyzed the characteristic traits and risk factors of parenchymal lung disease, which has been increasingly associated with systemic juvenile idiopathic arthritis.
Researchers demonstrated the role of an inflammatory subset of CD4 memory cells in patients with juvenile idiopathic arthritis who are in remission and will relapse on anti-TNF withdrawal.
Researchers evaluated Canadian claims level data to assess the utilization of methotrexate and prednisone in patients with JIA who initiated etanercept therapy.
Researchers assessed the efficacy and safety of leflunomide, as an alternative to methotrexate, in patients with juvenile idiopathic arthritis.
